Articles by Tyler Menichiello

  1. Targeting The Gut–Brain Axis With Live Biotherapeutic Products 9/8/2023

    Treating seizures with bacteria — Bloom Science's CEO, Dr. Christopher Reyes, explains how his company aims to leverage the gut–brain axis using live biotherapeutic products (LBP).

  2. ADC Advancements Allowing For Higher DAR 8/22/2023

    A high drug-antibody-ratio (DAR) used to mean higher off-target toxicity for ADCs. Now, thanks to improvements in linker technology and antibody targeting, higher DARs can allow for improved efficacy.

  3. How Linker Technology Is Driving ADC Development 8/4/2023

    If you’re still not excited about antibody drug conjugates (ADCs), “there’s an issue with you.” That’s the passionate, bullish sentiment (jokingly) held by Dr. Joe Daccache, project leader at DeciBio. Here, Daccache explains how innovations in linker technology are advancing the field of ADCs.

  4. Considerations For Licensing Platforms From Universities 6/16/2023

    Even the best platforms and technologies don’t come out of universities IND-ready. Just ask Coeptis Therapeutics, which recently licensed the novel CAR-T platform, SNAP-CAR, from the University of Pittsburgh. Coeptis’ Dave Mehalick, and Dan Yerace discuss the licensing agreement and the growing pains to expect when preparing a new platform for an IND.